Loading organizations...
§ Private Profile · Osterreicher, Steiermark, Austria
Precision diagnostics for hypertension. Mass spectrometry-based RAAS analysis screens for primary aldosteronism.
Based in Vienna, Austria, aTENSION.life develops precision diagnostic tests for hypertension using proprietary mass spectrometry-based analysis to support cardiovascular care. The company commercializes the ALDO+ platform, including the ALDO+PA test, which screens patients for primary aldosteronism through a single blood draw to facilitate targeted medical treatments. Operating within the precision medicine sector, the enterprise connects laboratories, physicians, and patients to address uncontrolled high blood pressure across international healthcare markets. In April 2025, the organization secured $3 million in seed funding through a financing round co-led by institutional investors Wlanholding, eQventure, and VP Venture Partners. Following the appointment of Werner Lanthaler as Chairman, the firm initiated the rollout of its diagnostic tools to early clinical customers throughout Germany, Switzerland, and the United States. The life sciences startup was established in 2024 by co-founders Bernhard Klemen and Marko Poglitsch.
aTENSION.life has raised $3.0M across 1 funding round.
aTENSION.life has raised $3.0M in total across 1 funding round.
aTENSION.life has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 7, 2025 | $3M Seed | Werner Lanthaler | Eqventure, Vp%20venture%20partners | Announced |
aTENSION.life has raised $3.0M in total across 1 funding round.
aTENSION.life's investors include Werner Lanthaler, eQventure, VP%20Venture%20Partners.